Antibody Fragment Conjugates
This approach uses a large molecular weight polyethylene glycol conjugated to antibody fragments. The specially designed PEG then becomes part of the antibody fragment Fc. Since the antibody fragment is more like a biologic, this conjugation has a branched architecture with either stable or degradable linkage.
Where might this conjugation technique be beneficial?
- Parenterally administered molecules
- Need to enhance pharmacokinetics
- The target of this conjugation is improved toxicity profile, extended half-life, and ease of synthesis with the antibody
Why use the Antibody Fragment Conjugates?
- Reduce antigenicity
- Reduce glomerular filtration rate
- Identify to proper linkage site to facilitate the re-production of identical conjugates from batch to batch
- Must still retain antigen-binding affinity and recognition
Technology Overview »